Exhibit 99.1

RMS Medical Products Posts Third Quarter 2017 Results

CHESTER, NY / December 27, 2016 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced its financial results for the third quarter of the fiscal year ending February 28, 2017.

For the quarter ended November 30, 2016, net revenues were $3,193,113, an increase of 1.5% compared with $3,144,954 in the same quarter last year.  This also represents an increase of 1.4% versus the last quarter.

For the nine months ended November 30, 2016, net revenues were $9,331,208, an increase of 4.4% compared with $8,941,676 for the same period last year, driven by increased sales of our infusion products to existing customers as well as the addition of new customers.  Excluding non-recurring clinical trial work in 2015, core revenue is up 6.5% for the most recent nine months.

For the three months ended November 30, 2016, gross profit was $2,063,943 compared with $2,109,279 for the same period last year.  This decrease in the quarter was mostly driven by the increases in sales rebates related to a specific customer contract renewal compared to the same period last year, as well as an increase in salary and related costs associated with increased staffing in our quality department to facilitate compliance with our quality management system.  RMS continues benefiting from lean manufacturing initiatives, which have increased capacity and decreased direct assembly labor costs, as well as the effects of a moratorium on the medical device tax.  For the nine months ended November 30, 2016, our gross profit margin increased to 63.8%, up from 63.0% for the same period last year.  Gross profit for the nine months ended November 30, 2016 was $5,955,346 compared with $5,633,868 for the comparable period last year.

RMS continues to incur professional fees related to regulatory and litigation and has made significant investment over the last nine months in its sales, regulatory, quality and operations management, including hiring a Chief Medical Officer, to help launch RMS to the next level of growth. As a result, the Company reported for this quarter ended November 30, a net loss of $104,275, compared to net income of $167,552 in the same period last year.  For the nine months ended November 30, 2016, net loss was $420,204 compared with net income of $438,126 for the same period last year.

Excluding consulting and professional fees related to regulatory and litigation (summarized in the attached tables), net income for the quarter ended November 30, 2016 would have been $281,197 compared with $352,694 for the same period last year.  For the nine months ended November 30, 2016, net income would have been $573,245 compared with $780,926 last year. Non-GAAP EBITDA for the quarter would have been $509,310 compared to $603,658 for last year and for the nine months would have been $1,095,662 compared with $1,387,308 for the same period last year.

Andy Sealfon, RMS CEO and President commented, “We are pleased to see some of our efforts internationally starting to come through with orders.”  Addressing the FDA Warning Letter, Mr. Sealfon noted: “We continue to work closely with the FDA in order to resolve the FDA Warning Letter. We have been and will continue to be proactive in working with the agency in order to resolve all issues that have been or may be raised by the agency as soon as possible.”